Cargando…

A Device Improves Signs and Symptoms of TMD

BACKGROUND: Temporomandibular joint dysfunction (TMD) therapy remains an open challenge for modern dentistry. Herein, we propose a new neuromuscular lingual device able to reduce signs and symptoms of TMD in female patients with chronic orofacial pain. METHODS: 50 females with myofascial TMD accordi...

Descripción completa

Detalles Bibliográficos
Autores principales: Monaco, Annalisa, Pietropaoli, Davide, IAPNOR, Cooper, Barry C., Ortu, Eleonora
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6526566/
https://www.ncbi.nlm.nih.gov/pubmed/31198477
http://dx.doi.org/10.1155/2019/5646143
_version_ 1783419913783738368
author Monaco, Annalisa
Pietropaoli, Davide
IAPNOR,
Cooper, Barry C.
Ortu, Eleonora
author_facet Monaco, Annalisa
Pietropaoli, Davide
IAPNOR,
Cooper, Barry C.
Ortu, Eleonora
author_sort Monaco, Annalisa
collection PubMed
description BACKGROUND: Temporomandibular joint dysfunction (TMD) therapy remains an open challenge for modern dentistry. Herein, we propose a new neuromuscular lingual device able to reduce signs and symptoms of TMD in female patients with chronic orofacial pain. METHODS: 50 females with myofascial TMD according to RDC/TMD were randomly assigned to study (n = 25) and control groups (n = 25). At T0, both groups received sEMG/KNG and pain evaluation by the VAS scale. The study group received the ELIBA device (lingual elevator by Balercia) constructed under ULF-TENS (ultra-low-frequency transcoutaneous electrical nervous stimulation). Subjects were instructed to use ELIBA at least for 16 h/day. After 6 months (T1), both groups underwent to sEMG/KNG and VAS revaluation. RESULTS: T1 study group compared to controls showed a significant reduction in total (p < 0.0001) and mean (p < 0.0001) sEMG values, as well as a significant increase in both maximum vertical mouth opening (p=0.003) and maximum velocity in mouth opening (p=0.003) and closing (p < 0.0001). Interestingly, a significant reduction in pain measured by VAS (p < 0.0001) was reported. CONCLUSIONS: After 6 months, the ELIBA device is able to significantly reduce TMD-associated myogenous pain and to promote the enhancement of sEMG/KNG values. Practical Implications. ELIBA can be considered as a new device, potentially useful for head-neck pain relief in patients suffering from chronic TMD. In addition, its use promotes a muscles relaxation inducing freeway space increase. This characteristic makes it particularly useful for rehabilitation of patients with not enough space for construction of conventional orthotics or neuromuscular bites.
format Online
Article
Text
id pubmed-6526566
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-65265662019-06-13 A Device Improves Signs and Symptoms of TMD Monaco, Annalisa Pietropaoli, Davide IAPNOR, Cooper, Barry C. Ortu, Eleonora Pain Res Manag Research Article BACKGROUND: Temporomandibular joint dysfunction (TMD) therapy remains an open challenge for modern dentistry. Herein, we propose a new neuromuscular lingual device able to reduce signs and symptoms of TMD in female patients with chronic orofacial pain. METHODS: 50 females with myofascial TMD according to RDC/TMD were randomly assigned to study (n = 25) and control groups (n = 25). At T0, both groups received sEMG/KNG and pain evaluation by the VAS scale. The study group received the ELIBA device (lingual elevator by Balercia) constructed under ULF-TENS (ultra-low-frequency transcoutaneous electrical nervous stimulation). Subjects were instructed to use ELIBA at least for 16 h/day. After 6 months (T1), both groups underwent to sEMG/KNG and VAS revaluation. RESULTS: T1 study group compared to controls showed a significant reduction in total (p < 0.0001) and mean (p < 0.0001) sEMG values, as well as a significant increase in both maximum vertical mouth opening (p=0.003) and maximum velocity in mouth opening (p=0.003) and closing (p < 0.0001). Interestingly, a significant reduction in pain measured by VAS (p < 0.0001) was reported. CONCLUSIONS: After 6 months, the ELIBA device is able to significantly reduce TMD-associated myogenous pain and to promote the enhancement of sEMG/KNG values. Practical Implications. ELIBA can be considered as a new device, potentially useful for head-neck pain relief in patients suffering from chronic TMD. In addition, its use promotes a muscles relaxation inducing freeway space increase. This characteristic makes it particularly useful for rehabilitation of patients with not enough space for construction of conventional orthotics or neuromuscular bites. Hindawi 2019-05-06 /pmc/articles/PMC6526566/ /pubmed/31198477 http://dx.doi.org/10.1155/2019/5646143 Text en Copyright © 2019 Annalisa Monaco et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Monaco, Annalisa
Pietropaoli, Davide
IAPNOR,
Cooper, Barry C.
Ortu, Eleonora
A Device Improves Signs and Symptoms of TMD
title A Device Improves Signs and Symptoms of TMD
title_full A Device Improves Signs and Symptoms of TMD
title_fullStr A Device Improves Signs and Symptoms of TMD
title_full_unstemmed A Device Improves Signs and Symptoms of TMD
title_short A Device Improves Signs and Symptoms of TMD
title_sort device improves signs and symptoms of tmd
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6526566/
https://www.ncbi.nlm.nih.gov/pubmed/31198477
http://dx.doi.org/10.1155/2019/5646143
work_keys_str_mv AT monacoannalisa adeviceimprovessignsandsymptomsoftmd
AT pietropaolidavide adeviceimprovessignsandsymptomsoftmd
AT iapnor adeviceimprovessignsandsymptomsoftmd
AT cooperbarryc adeviceimprovessignsandsymptomsoftmd
AT ortueleonora adeviceimprovessignsandsymptomsoftmd
AT monacoannalisa deviceimprovessignsandsymptomsoftmd
AT pietropaolidavide deviceimprovessignsandsymptomsoftmd
AT iapnor deviceimprovessignsandsymptomsoftmd
AT cooperbarryc deviceimprovessignsandsymptomsoftmd
AT ortueleonora deviceimprovessignsandsymptomsoftmd